{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:32:52Z","timestamp":1793201572243,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40123-025-01216-w","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T04:54:39Z","timestamp":1754715279000},"page":"2469-2479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Plasma Exchange for Severe Optic Neuritis in a Region with a High Prevalence of Neuromyelitis Optica"],"prefix":"10.1007","volume":"14","author":[{"given":"Marie","family":"Jugnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitta","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruddy","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Mehdaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-8249","authenticated-orcid":false,"given":"Harold","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","volume":"114","author":"H Merle","year":"2007","unstructured":"Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114:810\u20135.","journal-title":"Ophthalmology"},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","volume":"36","author":"MH Levin","year":"2013","unstructured":"Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013;36:159\u201371.","journal-title":"Prog Retin Eye Res"},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","volume":"35","author":"SM Gospe","year":"2021","unstructured":"Gospe SM, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye. 2021;35:753\u201368.","journal-title":"Eye"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021;96:59\u201377.","journal-title":"Neurology"},{"key":"1216_CR5","unstructured":"Trans-Atlantic Slave Trade - Database. Accessed November 21, 2023. https:\/\/www.slavevoyages.org\/voyage\/database."},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(02)11919-2","volume":"360","author":"SJ Hickman","year":"2002","unstructured":"Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002;360:1953\u201362.","journal-title":"Lancet"},{"key":"1216_CR7","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM Jr., The Optic Neuritis Study Group, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581\u20138.","DOI":"10.1056\/NEJM199202273260901"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1352458508100837","volume":"15","author":"M Bonnan","year":"2009","unstructured":"Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler J. 2009;15:487\u201392.","journal-title":"Mult Scler J"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (Add On) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858\u201362.","journal-title":"Arch Ophthalmol"},{"issue":"suppl 1","key":"1216_CR10","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1007\/s10875-010-9401-x","volume":"30","author":"A Vincent","year":"2010","unstructured":"Vincent A. Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems. J Clin Immunol. 2010;30(suppl 1):S97\u2013102.","journal-title":"J Clin Immunol"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:346\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40120-022-00344-w","volume":"11","author":"J Fu","year":"2022","unstructured":"Fu J, Wang Y, Li H, et al. Efficacy of plasma exchange treatment for demyelinating optic neuritis associated with various serum antibodies: a prospective cohort study. Neurol Ther. 2022;11:797\u2013813.","journal-title":"Neurol Ther"},{"key":"1216_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00415-016-8073-8","volume":"263","author":"R Deschamps","year":"2016","unstructured":"Deschamps R, Gueguen A, Parquet N, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol. 2016;263:883\u20137.","journal-title":"J Neurol"},{"key":"1216_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler J. 2016;22:185\u201392.","journal-title":"Mult Scler J"},{"key":"1216_CR15","volume":"13","author":"MC Mason","year":"2021","unstructured":"Mason MC, Marotta DA, Kesserwani H. Steroid-resistant double-seronegative optic neuritis responds favorably to plasma exchange. Cureus. 2021;13: e15260.","journal-title":"Cureus"},{"key":"1216_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"1216_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53:1107\u201314.","journal-title":"Neurology"},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20139.","journal-title":"Neurology"},{"key":"1216_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"1216_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22:268\u201382.","journal-title":"Lancet Neurol"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.","journal-title":"J Neuroinflammation"},{"key":"1216_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archophthalmol.2010.16","volume":"128","author":"JL Keltner","year":"2010","unstructured":"Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW. Visual field profile of optic neuritis. A final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol. 2010;128:330\u20137.","journal-title":"Arch Ophthalmol"},{"key":"1216_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","volume":"252","author":"JJ Chen","year":"2023","unstructured":"Chen JJ, Flanagan EP, Pittock SJ, et al. Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks. Am J Ophthalmol. 2023;252:213\u201324.","journal-title":"Am J Ophthalmol"},{"key":"1216_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","volume":"94","author":"J Rode","year":"2023","unstructured":"Rode J, Pique J, Maarouf A, et al. Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry. 2023;94:309\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1216_CR25","first-page":"527","volume":"27","author":"J Avasarala","year":"2022","unstructured":"Avasarala J, Zachariah P, Turner B. Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity? NS Spectr. 2022;27:527\u20139.","journal-title":"NS Spectr"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834\u201349.","journal-title":"Brain"},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/acn3.52268","volume":"12","author":"AM Carlson","year":"2025","unstructured":"Carlson AM, Sollero CEV, Wolf AB, et al. The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population. Ann Clin Transl Neurol. 2025;12:169\u201379.","journal-title":"Ann Clin Transl Neurol"},{"key":"1216_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","volume":"63","author":"K Ruprecht","year":"2004","unstructured":"Ruprecht K, Klinker E, Dintelmann T, Rieckman P, Gold R. Plasma exchange for severe neuromyelitis optica. Treatment of 10 patients. Neurology. 2004;63:1081\u20133.","journal-title":"Neurology"},{"key":"1216_CR29","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s10792-019-01090-z","volume":"39","author":"W Song","year":"2019","unstructured":"Song W, Qu Y, Huang X. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol. 2019;39:2477\u201383.","journal-title":"Int Ophthalmol"},{"key":"1216_CR30","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000008551","volume":"93","author":"A Savransky","year":"2019","unstructured":"Savransky A, Rubstein A, Huaman Rios M, et al. Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination. Neurology. 2019;93:e2065\u201373.","journal-title":"Neurology"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/jop.2009.0150","volume":"26","author":"H Yoshida","year":"2010","unstructured":"Yoshida H, Ando A, Sho K, et al. Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis. J Ocul Pharmacol Ther. 2010;26:381\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","volume":"18","author":"KC Wang","year":"2011","unstructured":"Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci. 2011;18:43\u20136.","journal-title":"J Clin Neurosci"},{"key":"1216_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.951423","volume":"13","author":"S Chatterton","year":"2022","unstructured":"Chatterton S, Parratt JDE, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol. 2022;13: 951423.","journal-title":"Front Neurol"},{"key":"1216_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10072-023-06971-x","volume":"45","author":"D Gorriz","year":"2024","unstructured":"Gorriz D, P\u00e9rez-Miralles FC, Quintanilla-Bordas C, et al. Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci. 2024;45:249\u201351.","journal-title":"Neurol Sci"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01216-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01216-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01216-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T10:41:26Z","timestamp":1757068886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01216-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01216-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Marie Jugnet, Thomas David, Mitta Pierre, Ruddy Valentino, Hossein Mehdaoui, and Harold Merle have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors received consent from each participant. The study protocol was reviewed and approved by the Institutional Review Board of the University Hospital of Martinique (CPP: Comit\u00e9 de Protection des Personnes), IRB number 2024\/043. The primary mission of the CPP is to ensure the ethical implementation of research. They carry out their mission with a constant concern for the protection of individuals from both a legal and ethical perspective. The study procedures were fulfilled in agreement with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}